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SUMMARY OF PRESENTATIONS
Positron Emission Tomography/Computed
Tomography as Early Response Marker for
Chemoradiation for Stage III NSCLC
Dr. Wally Curran discussed whether positron emission to-
mography-computed tomography (PET-CT) is sufficiently
robust to use as an earlier marker of benefit in patients with
locally advanced non-small cell lung cancer (NSCLC) be-
cause survival outcomes require a greater than 2-year patient
follow-up period. Currently, FDG-PET-CT is used as a diag-
nostic aid for the workup of pulmonary nodules, staging
utility for the mediastinum, and staging for distant metasta-
ses. ACRIN 6668/RTOG 0235 addresses the role of FDG
PET scan to predict outcomes in patients with locally ad-
vanced NSCLC treated with chemoradiation. In this study,
235 patients with locally advanced NSCLC underwent pre-
treatment FDG-PET, then concurrent chemoradiation, fol-
lowed by repeat FDG-PET 12 to 16 weeks after the comple-
tion of radiation. Central review of the mean SUVpeak was
highly correlated. Median SUV values dropped from 9.4
(pretreatment) to 2.5 (posttreatment). More follow-up is
needed before one could discern the utility of posttherapy
FDG PET in predicting outcomes. Kong et al. evaluated
midcourse FDG-PET (40–50 Gy) and post-RT PET, which
showed a trend toward improved PFS if SUV during RT less
than 3.0.1 A follow-up study has been proposed: pretreatment
FDG-PET, followed by concurrent chemoradiation to 44 Gy.
A midcourse FDG-PET would be performed. If the patient
had progressive disease, the patient would be taken off study
and discontinue radiation. If the patient demonstrated stable
disease or response, they would be randomized to continue
radiation to 64 Gy or radiation to 64 Gy, then followed by a
10-Gy boost based on the results of the FDG-PET.
Combined Modality Therapy with EGFR and
Radiation
Dr. Hak Choy discussed the results of three trials (SWOG
0023, RTOG 0324, and CALGB 30407) combining EGFR
therapy with radiation. The first study SWOG 0023 combined
two cycles of cisplatin and etoposide with concurrent thoracic
radiation followed by three cycles of consolidation therapy with
docetaxel followed by maintenance therapy with gefitinib versus
placebo. Unfortunately, the gefitinib arm demonstrated a worse
median overall survival compared with placebo (23 versus 35
months, p  0.01). The second study RTOG 0324 combined
weekly treatment of paclitaxel, carboplatin, and cetuximab with
once daily thoracic radiotherapy followed by consolidation ther-
apy with paclitaxel, carboplatin, and cetuximab. The trial dem-
onstrated a median survival of 22.7 months and 2-year survival
of 49.3%. These results were much higher than historical RTOG
controls (median survival range, 14.6–17.3 months). The ongo-
ing RTOG 0617 trial uses a four-arm, 2  2 factorial design
with radiotherapy of 60 versus 74 Gy, cetuximab plus chemo-
therapy (paclitaxel and carboplatin) versus chemotherapy alone
to study this concept further. Currently, 209 of an anticipated
500 patients are enrolled. A third study CALGB 30407 combin-
ing pemetrexed, carboplatin, and thoracic radiotherapy 6600
Gy  cetuximab was demonstrated to be feasible and well
tolerated.Median survival was 22months, with a trend of increased
survival in patients with nonsquamous histology. Unfortunately,
there was no significant benefit to the addition of cetuximab to
chemotherapy with maintenance beyond four cycles not being
feasible in nearly half the patients enrolled in this study.
Radiation Therapy and Angiogenesis Inhibitors
Dr. Michael O’Reilly discussed several trials evaluating
the combination of radiation therapy and angiogenesis inhibi-
tors. The National Cancer Institute of Canada Clinical trials
Group Study BR.20 demonstrated a trend toward improved
survival in patients with limited-stage small cell lung cancer
treated with chemoradiation followed by vandetanib (ZD6474),
a vascular endothelial growth factor (VEGF) and epidermal
growth factor receptor agonist.2 Vandetanib is also currently
undergoing a phase I/II study in NSCLC. In the phase I portion,
patients will be treated with ZD6474 followed by radiation. In
the phase II setting, patients will receive palliative radiation (45
Gy) and ZD 6474, definitive radiotherapy (63 Gy) and ZD 6474
after induction chemotherapy, or definitive radiotherapy (66–70
Gy) and ZD 6474 for stage I inoperable patients.
Enthusiasm for angiogenesis inhibitors combined with
radiation has been tempered recently with concern for side
effects. Spigel et al. reported tracheoesophageal (TE) fistula in 6
of 35 patients with small cell or non-small cell lung cancer
treated with bevacizumab and chemoradiation.3 In a study of
patients with small cell lung cancer treated with irinotecan,
carboplatin, bevacizumab, and thoracic radiotherapy, the overall
response rate was 88% with four complete responses and 11
partial responses. Nevertheless, two patients developed two TE
fistulae (one which was fatal) prompting early closure. In addi-
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tion, there was one death due to aerodigestive hemorrhage and
one death due to treatment-related bowel perforation. In a study
of patients with non-small cell lung cancer treated with pem-
etrexed, carboplatin, bevacizumab, and thoracic radiotherapy,
two patients developed TE fistulae, again prompting early study
closure. Given these adverse effects, antiangiogenic therapies
offer great potential, but it is unclear how to optimize their use
with radiation therapy.
Role of Radiation in Small Cell Lung Cancer
Dr. Ritsuko Komaki discussed the role of radiother-
apy in small cell lung cancer. In the RTOG 0239, patients
with limited stage small cell lung cancer (LS-SCLC) were
treated with two cycles of cisplatin and etoposide with
concurrent thoracic radiation 61.2 Gy in 1.8 Gy/fraction
with 1.8 Gy twice daily boost off cord over 5 weeks.
Median survival was 19 months with a 2-year survival rate
of 37%. Two grade 5 toxicities (neutropenic sepsis and
pneumonia) were reported. Patterns of failure were 20%
local recurrence and 44% distant metastases. The current
intergroup study CALGB 30610/RTOG 0538 treat patie-
nts with LS-SCLC with four cycles of cisplatin and eto-
poside with concurrent thoracic radiotherapy (45 Gy in 3
weeks with 1.5 Gy twice daily, 61.2 Gy in 5 weeks with
Con boost, and 70 Gy in 7 weeks with 2.0 Gy once daily)
followed by prophylactic cranial irradiation 25 Gy in 10
fractions. The target accrual is 700 patients, evaluating
overall survival and several correlative studies. In addi-
tion, prophylactic cranial irradiation should be offered to
patients with SCLC who achieve complete response. Fu-
ture directions include clinical investigation of VEGF
receptor or VEGF/epidermal growth factor receptor inhib-
itors with chemoradiation in patients with SCLC.
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